Considering that PI3K/Akt signaling activation has been shown to promote therapy resistance in breast cancers 31-33, these data suggested that CapG may promote drug resistance through modulating PI3K/Akt signaling pathways in breast cancer cells. This evidence concerns the gene CAPG and breast carcinoma.